GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common ED drug boost chemo for stomach cancer?
Disease control Recruiting nowThis study tests whether adding tadalafil (a drug for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will take tadalafil alone for two weeks, then combined with chemo for…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
Could Belly-Infused chemotherapy stop stomach cancer in its tracks?
Disease control Recruiting nowThis study is for people with stomach cancer that has spread to the lining of the abdomen. It compares standard chemotherapy given through a vein to the same treatment plus an extra chemotherapy drug (paclitaxel) delivered directly into the belly through a small port. The goal is…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
Stomach cancer patients may soon get treatment as a simple shot
Disease control Recruiting nowThis study tests if a shot under the skin works as well as an IV drip for a cancer drug (tislelizumab) combined with chemotherapy in adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 351 participants will recei…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
Engineered immune cells target stomach cancer in new trial
Disease control Recruiting nowThis study tests a special immune cell therapy called CT041 CAR-T in 20 adults with advanced stomach or gastroesophageal junction cancer. The treatment is given after standard first-line therapy to see if it can delay cancer growth. Participants receive their own immune cells tha…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
New drug targets tough cancers: early trial seeks safer, smarter treatment
Disease control Recruiting nowThis early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
New hope for stomach cancer patients: experimental drug targets HER2-positive tumors
Disease control Recruiting nowThis study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that is HER2-positive and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-M07D1 or standard che…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
Radiation-Activated nanoparticle targets esophageal tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation therapy to destroy cancer cells. It is given alongside standard chemotherapy for people with esophageal adenocarcinoma. The main goals are to find the safest dose an…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests a new drug (sonesitatug vedotin) plus chemotherapy, with or without another drug (rilvegostomig), in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. About 2,130 participants…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New pill shows promise for Hard-to-Treat brain cancers
Disease control Recruiting nowThis study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New cancer drug KK2269 enters first human safety trial
Disease control Recruiting nowThis early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for stomach cancer: targeted combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug combo trial aims to tame tough cancers
Disease control Recruiting nowThis early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The main goal is to check safety and find the right dose. About 1,000 participants will join this study t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for stomach cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called SHR2554 combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors. About 351 …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New chemo cocktail tailored to your genes shows promise for tough cancers
Disease control Recruiting nowThis early-phase study tests a new combination of five chemotherapy drugs for people with advanced cancers of the upper digestive system, including pancreatic and stomach cancers. The goal is to find the safest dose based on a person's genetic makeup, which affects how the body p…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Triple therapy may turn inoperable stomach cancer into surgical candidates
Disease control Recruiting nowThis study is for people with advanced gastroesophageal junction cancer that cannot be removed with surgery. It tests a combination of targeted radiation, immunotherapy, and chemotherapy to shrink the tumor enough so that surgery becomes possible. About 88 adults will take part t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Hope for stomach cancer: new combo aims to outperform standard care
Disease control Recruiting nowThis study tests a new drug combination (rilvegostomig plus chemotherapy and trastuzumab deruxtecan) against the current standard treatment for advanced HER2-positive stomach cancer. About 840 adults whose cancer has spread and who have not had prior treatment will participate. T…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New hope for stomach cancer: drug combo shows promise in Real-World study
Disease control Recruiting nowThis study looks at how well a drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The cancer must have a specific protein (claudin 18.2) on its surface. The goal is to see i…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: European Institute of Oncology • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New pill combo shows promise against hard-to-treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental pill called zongertinib, which blocks HER2—a protein that makes cancer grow. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and hasn't responded to prior treatments. The study has two parts: first, findi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New triple therapy before surgery shows promise for tough stomach cancer
Disease control Recruiting nowThis study is for people with a certain type of cancer where the stomach meets the esophagus. It tests if giving a special kind of radiation together with immunotherapy and chemotherapy before surgery is safe and works better. About 84 adults with advanced but removable cancer wi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New hope for stomach cancer patients who failed immunotherapy: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that has worsened after or was not tolerated during first-line immunotherapy. The goal is to see if the combination …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jingdong Zhang • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Robotic surgery and heated chemo offer new hope for stomach cancer patients
Disease control Recruiting nowThis study tests a new way to treat stomach cancer that has spread to the lining of the abdomen. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the belly during surgery. The goal is to help patients recover faster and have few…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for stomach cancer spread? drug combo trial opens at mayo clinic
Disease control Recruiting nowThis early-stage study tests whether adding a drug called aldesleukin (IL-2) to standard immunotherapy and chemotherapy can better control stomach cancer that has spread to the abdomen lining. About 15 adults with this condition will receive the combination. The goal is to see if…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Cancer-killing virus injected directly into tumors combined with immunotherapy shows promise in hard-to-treat cancers
Disease control Recruiting nowThis study tests a new combination treatment for people with advanced stomach, esophageal, or gastroesophageal junction cancer that has not responded to standard therapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into their tumor during a scope …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for Hard-to-Treat cancers: experimental drug targets tumors
Disease control Recruiting nowThis study tests an experimental drug called PF-08046050 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to stick to cancer cells and kill them. The main goal is to check safety and find the right dose. About 914 adults wi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New drug cocktail aims to wipe out esophageal cancer before standard treatment
Disease control Recruiting nowThis study tests whether adding a new drug (liposomal irinotecan) to standard chemotherapy before chemoradiation can completely eliminate cancer in people with advanced gastroesophageal junction or esophagogastric cancer. About 40 adults with stage T3/4 or node-positive disease w…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Cancer patients may soon get immunotherapy at home – no more long clinic trips!
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 16, 2026 22:26 UTC
-
2000 volunteers help create a 'Library' to spot cancer earlier
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Massive german registry tracks real-world cancer care for 1,900 patients
Knowledge-focused Recruiting nowThis study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday practice in Germany. It will include about 1,900 adults starting their first palliative therapy. The goal is to unders…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 11, 2026 20:38 UTC